8-K: Lucid Diagnostics Initiates $25 Million At-The-Market Equity Offering Program

Lucid Diagnostics Inc. has established an at-the-market equity offering program to sell up to $25 million of its common stock, aiming to bolster working capital and support general corporate purposes.

Summary

• Lucid Diagnostics Inc. (the "Company") has entered into a Sales Agreement with Maxim Group LLC to implement an "at-the-market" (ATM) equity offering program.
• Under this Agreement, the Company is authorized to offer and sell shares of its common stock from time to time, through or to Maxim Group LLC, acting as a sales agent.
• The maximum aggregate gross sales proceeds for shares sold under this program is capped at $25,000,000.
• Lucid Diagnostics will compensate Maxim Group LLC with a commission of 3.0% of the total gross sales prices of the shares.
• Additionally, the Company will reimburse the Agent for legal counsel fees, with an initial amount not exceeding $60,000 and subsequent quarterly payments not exceeding $7,500.
• The net proceeds generated from this offering are designated for the Company's working capital and general corporate purposes.
• This offering is being conducted under the Company's effective shelf registration statement on Form S-3 (File No. 333-268560), which became effective on December 6, 2022, and a related prospectus supplement filed on May 30, 2025.

Sentiment

Score: 7

Explanation: The establishment of an ATM offering provides Lucid Diagnostics with a flexible and efficient means to raise capital, which is generally positive for a company's financial stability and ability to fund operations and growth. While it introduces potential dilution, the access to capital for working capital and general corporate purposes is a beneficial development.

Positives

• Provides Lucid Diagnostics with a flexible and efficient mechanism to raise capital incrementally, adapting to market conditions.
• Enhances the Company's financial liquidity and flexibility by securing funds for working capital and general corporate purposes, supporting ongoing operations and potential strategic initiatives.
• The ATM structure allows for capital raises without the immediate, significant market impact often associated with large, fixed-price underwritten offerings.

Negatives

• The issuance of new common stock under the ATM program will result in dilution for existing shareholders.
• The actual amount and timing of capital raised are uncertain, dependent on market demand and the Company's discretion, which could lead to unpredictable funding availability.
• The Company will incur costs associated with the offering, including a 3.0% commission on gross sales and legal reimbursement fees to the agent.

Risks

• **Market Conditions**: The success and pricing of share sales under the ATM program are subject to prevailing market conditions, which can be volatile and unpredictable.
• **Dilution**: Future sales of common stock will dilute the ownership interest and potentially the earnings per share of current shareholders.
• **Share Price Volatility**: Continuous or significant sales of shares could exert downward pressure on the Company's stock price.
• **No Sales Guarantee**: There is no assurance that Maxim Group LLC will be successful in selling any Placement Shares, meaning the Company may not raise the full $25 million.
• **Compliance Burden**: The Company bears sole responsibility for ensuring compliance with all limitations on the number or dollar amount of shares that can be sold under the agreement and relevant SEC rules.

Future Outlook

The Company intends to use any net proceeds from the at-the-market offering for working capital and general corporate purposes. This provides Lucid Diagnostics with financial flexibility to support ongoing operations, fund strategic initiatives, and adapt to future business needs.

Management Comments

• Dennis McGrath, Chief Financial Officer of Lucid Diagnostics Inc., signed the Form 8-K on behalf of the registrant, formally indicating the Company's entry into the Sales Agreement.

Industry Context

At-the-market (ATM) offerings are a standard and increasingly popular financing tool for publicly traded companies across various sectors, including diagnostics and biotechnology. These programs provide companies with flexible access to capital, allowing them to raise funds incrementally based on market demand and specific funding requirements, which is particularly beneficial for industries that require continuous investment in research, development, and market penetration.

Comparison to Industry Standards

• Not applicable. This filing details a financing mechanism (an ATM offering) rather than operational or financial performance. Therefore, direct comparisons to industry-specific benchmarks, competitor results, or global project standards are not relevant in this context. ATM offerings are a widely adopted capital-raising strategy across diverse industries.

Stakeholder Impact

• **Shareholders**: Potential for dilution of existing shareholdings as new common stock is issued into the market.
• **Company Operations**: Enhanced financial flexibility to support working capital needs and general corporate purposes, potentially enabling continued investment in strategic initiatives and operational stability.

Next Steps

• The Company may, from time to time, issue and sell shares of common stock through Maxim Group LLC under the ATM program.
• The Company is obligated to file prospectus supplements and periodic reports (Form 10-Q, 10-K) with the SEC, disclosing the number of shares sold and net proceeds during relevant periods.
• The Company will continue to maintain compliance with all applicable SEC regulations and Nasdaq listing requirements.

Key Dates

Keywords

Lucid Diagnostics, LUCD, At-The-Market Offering, ATM, Equity Offering, Capital Raise, Common Stock, SEC Filing, Form 8-K, Maxim Group LLC, Dilution, Working Capital, Corporate Finance